OBIO

Orchestra BioMed Holdings, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.35
52-Week Range: $2.66 – $6.50
Market Cap: $357.63M
P/E (TTM): —
EPS (TTM): -0.86
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 18.54
PEG Ratio: —
Return on Equity: -397.30%
Return on Assets: -45.73%
Gross Margin: 99.51%
Operating Margin: -25404.55%
Profit Margin: -184.60%
Current Ratio: 8.26
Debt/Equity: 2.41
Total Debt: $70.76M
Free Cash Flow: $-31.81M
Revenue Growth: -89.50%
Earnings Growth: —
Enterprise Value: $328.52M

OBIO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.53M	$2.76M	$2.64M	$33.48M
Cost of Revenue	$211.00K	$186.00K	$204.00K	$190.00K
Gross Profit	$3.32M	$2.57M	$2.43M	$33.29M
Research & Development	$21.95M	$33.82M	$42.80M	$58.19M
Selling, General & Admin	$14.03M	$20.26M	$23.93M	$26.91M
Operating Expenses	$35.98M	$54.08M	$66.73M	$85.10M
Operating Income	-$32.66M	-$51.51M	-$64.30M	-$51.81M
EBITDA	-$32.44M	-$51.22M	-$63.99M	-$51.23M
Pretax Income	-$33.61M	-$49.12M	-$61.02M	-$52.70M
Net Income	-$33.61M	-$49.12M	-$61.02M	-$52.70M
Diluted EPS	-1.06	-1.48	-1.66	-1.11
Diluted Shares	31.61M	33.23M	36.82M	47.75M

OBIO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.78M	$30.56M	$22.26M	$34.69M
Receivables	$96.00K	$99.00K	$92.00K	$95.00K
Inventory	$276.00K	$146.00K	$173.00K	$310.00K
Current Assets	$84.69M	$89.11M	$69.17M	$107.91M
Total Assets	$95.57M	$95.21M	$76.17M	$114.86M
Current Liabilities	$18.57M	$11.21M	$16.21M	$16.74M
Long-Term Debt	$9.49M	—	$14.29M	$14.27M
Total Debt	$11.87M	$1.69M	$16.53M	$15.96M
Total Liabilities	$43.04M	$27.17M	$43.22M	$61.29M
Retained Earnings	-$199.73M	-$248.85M	-$309.88M	-$362.58M
Shareholders' Equity	$52.53M	$68.04M	$32.96M	$53.57M
Working Capital	$66.12M	$77.91M	$52.96M	$91.17M

OBIO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.29M	-$46.13M	-$50.56M	-$48.96M
Capital Expenditure	-$591.00K	-$78.00K	-$289.00K	-$489.00K
Free Cash Flow	-$29.88M	-$46.20M	-$50.85M	-$49.45M
Depreciation & Amortisation	$222.00K	$287.00K	$308.00K	$327.00K
Stock-Based Compensation	$3.41M	$7.63M	$10.62M	$11.98M
Investing Cash Flow	-$64.12M	$10.69M	$13.09M	-$26.94M
Financing Cash Flow	$103.26M	$46.22M	$29.17M	$88.33M
Net Change in Cash	$9.85M	$10.78M	-$8.30M	$12.43M

OBIO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$868.00K	$836.00K	$861.00K	$30.92M	$110.00K	$88.00K
Cost of Revenue	$44.00K	$46.00K	$49.00K	$51.00K	$32.00K	$25.00K
Gross Profit	$824.00K	$790.00K	$812.00K	$30.87M	$78.00K	$63.00K
Research & Development	$13.48M	$13.85M	$14.03M	$16.82M	$15.78M	$16.59M
Selling, General & Admin	$6.26M	$6.26M	$7.10M	$7.29M	$6.37M	$5.83M
Operating Expenses	$19.75M	$20.12M	$21.13M	$24.11M	$22.15M	$22.42M
Operating Income	-$18.92M	-$19.33M	-$20.31M	$6.75M	-$22.08M	-$22.36M
EBITDA	-$18.84M	-$19.25M	-$20.23M	$7.09M	-$21.99M	-$22.26M
Pretax Income	-$18.75M	-$19.36M	-$20.83M	$6.25M	-$20.69M	-$23.75M
Net Income	-$18.75M	-$19.36M	-$20.83M	$6.25M	-$20.69M	-$23.75M
Diluted EPS	-0.49	-0.50	-0.40	—	-0.33	-0.38
Diluted Shares	38.24M	38.39M	52.19M	—	62.72M	63.81M

OBIO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$18.35M	$18.75M	$42.01M	$34.69M	$28.37M	$20.47M
Receivables	$89.00K	$83.00K	$52.00K	$95.00K	$84.00K	$51.00K
Inventory	$135.00K	$185.00K	$365.00K	$310.00K	$277.00K	$250.00K
Current Assets	$51.90M	$35.88M	$97.77M	$107.91M	$96.21M	$111.24M
Total Assets	$59.05M	$42.83M	$104.81M	$114.86M	$100.66M	$115.70M
Current Liabilities	$15.49M	$17.06M	$20.66M	$16.74M	$13.69M	$13.47M
Long-Term Debt	$14.34M	$14.38M	$14.20M	$14.27M	$14.33M	$34.84M
Total Debt	$16.44M	$16.35M	$16.04M	$15.96M	$15.85M	$36.17M
Total Liabilities	$42.19M	$42.53M	$61.07M	$61.29M	$59.47M	$96.38M
Retained Earnings	-$328.63M	-$348.00M	-$368.82M	-$362.58M	-$383.27M	-$407.02M
Shareholders' Equity	$16.86M	$295.00K	$43.74M	$53.57M	$41.19M	$19.32M
Working Capital	$36.41M	$18.82M	$77.11M	$91.17M	$82.52M	$97.77M
Net Debt	—	—	—	—	—	$14.37M

OBIO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$16.62M	-$15.53M	-$14.55M	-$2.27M	-$22.17M	-$19.33M
Capital Expenditure	-$112.00K	-$34.00K	-$310.00K	-$33.00K	-$184.00K	-$254.00K
Free Cash Flow	-$16.73M	-$15.56M	-$14.86M	-$2.30M	-$22.35M	-$19.59M
Depreciation & Amortisation	$83.00K	$81.00K	$81.00K	$82.00K	$90.00K	$96.00K
Stock-Based Compensation	$2.96M	$3.25M	$3.01M	$2.75M	$2.85M	$2.50M
Investing Cash Flow	$13.00M	$16.36M	-$38.58M	-$17.71M	$10.32M	-$23.31M
Financing Cash Flow	-$296.00K	-$428.00K	$76.40M	$12.66M	$5.53M	$34.75M
Net Change in Cash	-$3.91M	$401.00K	$23.26M	-$7.32M	-$6.32M	-$7.89M

Market Snapshot

About

Orchestra BioMed Holdings, Inc. develops biomedical innovations focused on treating cardiovascular and vascular diseases with novel medical devices and therapies.